DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM - Seite 2

Development Officer at Debiopharm .

"We always have immense gratitude for our patients who participate in first time
in human trials, but in this case, we are particularly thankful for our patient
who agreed to be the first person in the world to have their kidney cancer
imaged with Debio 0328 on the GaLuCiTM trial. We hope this is the beginning of
the theranostics era in kidney cancer!" expressed Dr. Ben Tran, Lead
Genito-urinary medical oncologist, Peter MacCallum Cancer Centre.

"We are excited about this first-in-human study as it is a novel approach for
advanced kidney cancer patients," said Darren R. Feldman, MD, Associate
Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering
Cancer Center . "Precision nuclear medicine applied to CA9 could benefit
advanced cancer patients who still experience a high unmet medical need. This
theranostic pair allows targeted radiation delivery to the cancer cells bearing
CA IX, which is largely expressed, over 85%, in clear cell renal cell
carcinoma."

The theranostic approach with Debio 0228/0328

Debio 0228 ( [177Lu]Lu-DPI-4452 ) and 0328 ( [68Ga]Ga-DPI-4452 ) is an
investigational theranostic pair originally discovered by 3B Pharmaceuticals
GmbH and exclusively licensed to Debiopharm. ( [68Ga]Ga-DPI-4452 is a PET
imaging agent, (Debio 0328) used to identify patients whose cancers overexpress
CA IX. Once identified, these patients can be treated with the lutetium-labelled
radioligand, Debio 0228, which delivers targeted radiation to the tumor,
destroying it from the inside.

Debiopharm's commitment to patients

Debiopharm aims to develop innovative therapies that target high unmet medical
needs in oncology and bacterial infections. Bridging the gap between disruptive
discovery products and real-world patient reach, we identify high-potential
compounds and technologies for in-licensing, clinically demonstrate their safety
and efficacy, and then select large pharmaceutical commercialization partners to
maximize patient access globally.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews

Contact:

Dawn Bonine
Head of Communications
mailto:[e-mail]
Tel: [phone]

Additional content: http://presseportal.de/pm/121610/5469356
OTS: Debiopharm International SA